Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EVO301 · 1 trial · 3 indications
EASI assesses the extent and severity of atopic dermatitis. EASI is a composite index with scores ranging from 0 to 72. Higher values indicate more severe or extensive disease.
| Arm | Type | Description |
|---|---|---|
| Intravenous EVO301 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| EVO301 | BIOLOGICAL | Intravenous EVO301 |
| Placebo | BIOLOGICAL | Placebo |
Inclusion Criteria: 1. Males or non-pregnant, non-lactating females, age 18 years or older 2. Chronic atopic dermatitis for at least 6 months 3. BSA of AD involvement of at least 10% 4. EASI score of at least 16. Exclusion Criteria: 1. Significant AD flare with 4 weeks 2. Use of biologic therapy ...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
EVO301 is an investigational monoclonal antibody being studied for the treatment of moderate to severe atopic dermatitis, a chronic inflammatory skin condition also known as eczema. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
EVO301 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. The drug is being evaluated for its efficacy in treating atopic dermatitis, though the precise biological pathway it modulates remains unspecified.
EVO301 is being developed by Evommune, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol EVMN. Evommune is conducting clinical research to evaluate the drug's safety and efficacy in patients with atopic dermatitis.
EVO301 is in Phase 2 clinical development. A Phase 2 trial has been completed, and the drug remains investigational, meaning it has not yet received approval from regulatory agencies such as the FDA. Further studies may be needed to establish its safety and effectiveness.
EVO301 has one completed Phase 2 clinical trial registered under NCT06723405, titled 'Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis.' The randomized, double-blind, placebo-controlled study enrolled 71 participants aged 18 years and older in Australia and New Zealand.
No alternative names for EVO301 have been reported. The drug is identified solely by its code name EVO301 and is being developed by Evommune, Inc. for the treatment of atopic dermatitis.